

---

HOUSE BILL 1937

---

State of Washington                      54th Legislature                      1995 Regular Session

By Representatives Cole, Cody, Veloria and Conway

Read first time 02/15/95. Referred to Committee on Health Care.

1            AN ACT Relating to the board of pharmacy; and adding new sections  
2 to chapter 18.64 RCW.

3 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

4            NEW SECTION.    **Sec. 1.**    The legislature finds that significant  
5 errors continue to occur in our state's hospitals as well as in  
6 physician's and dentist's offices with the use of medications packaged  
7 in ampules, vials, or prefilled syringes. These errors pose serious  
8 health hazards to the public and subject manufacturers, dispensers, and  
9 prescribers of legend drugs to potential legal liability. These  
10 misidentification errors result in large part as a consequence of human  
11 error in failing to adequately distinguish between and among the  
12 multitude of options available because of the lack of consistent and  
13 systematic markings and colorings on the container.

14            In order to minimize the occurrence of these errors, the  
15 legislature declares the need for adopting a rational identification  
16 and labeling system for all legend drugs that are furnished in ampules,  
17 vials, and prefilled syringes.

1        NEW SECTION.    **Sec. 2.** By June 30, 1996, the board of pharmacy is  
2 directed to develop and adopt by rule requirements for an  
3 identification and labeling system for all legend drugs that are  
4 furnished in ampules, vials, and prefilled syringes. The board shall  
5 consider the standards and recommendations of the American society for  
6 testing and materials, and consult with appropriate federal and state  
7 agencies, and professional and pharmaceutical associations in the  
8 development of the rules.

9        NEW SECTION.    **Sec. 3.** The rules shall not be in full force and  
10 effect until January 1, 1998, unless the board makes a finding that an  
11 identification and labeling system that is substantively equivalent to  
12 that established by the rules of the board has been adopted by the  
13 federal food and drug administration or other competent federal  
14 authority before the effective date of the rules.

15        NEW SECTION.    **Sec. 4.** The board shall consider in the  
16 identification system the necessity for the imprinting of the trade or  
17 generic name of the legend drug that is recognizable under appropriate  
18 lighting conditions; the color coding of tips of ampules, the caps of  
19 vials, as well as the labels of prefilled syringes to enhance rapid and  
20 accurate identity; and warnings for the dilution of legend drugs prior  
21 to use, as well as other requirements the board finds necessary to  
22 protect the public health.

23        NEW SECTION.    **Sec. 5.** Sections 1 through 4 of this act are each  
24 added to chapter 18.64 RCW.

--- END ---